TTP LabTech Announce US Expansion to Meet Growing Customer Demand
News Jul 30, 2007
TTP LabTech has announced the further expansion of its US facilities with the recruitment of sales and customer service personnel for its East Coast office in Cambridge, MA.
Driven by increasing sales of mosquito®, comPOUND® and Acumen® eX3, TTP LabTech has recruited Doug Mann to its support division as a Field Service Engineer.
Doug brings with him many years of automation experience and joins the US Sales & Support Manager, Ben Schenker, recently relocated from the company’s UK headquarters.
TTP LabTech Inc’s new US headquarters in Cambridge, MA, will serve to support customer needs and the increasing demand for TTP LabTech products in North America. This announcement follows the recent appointment of distributors in Japan, India and Australia, demonstrating TTP LabTech’s growing customer appeal and global outreach.
According to Ben Schenker, “TTP LabTech is celebrating 20 years in automation in 2007. This, along with our greatly increased worldwide presence and expanded US office, makes it a very exciting time for the company and the response from customers has been tremendous”.
Commercial Director, Jas Sanghera, says the US expansion has been fuelled by customer demand for TTP LabTech’s wide range of innovative instrumentation and excellent technical expertise. “We have wanted to expand our team of highly qualified scientists and engineers to support the life science hubs on the East Coast and are delighted to have such an experienced team on board.”
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019